Terms: = Ovarian cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
369 results:
1. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
Çoban HŞ; Çil N; Önder E; Abban Mete G
Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
[TBL] [Abstract] [Full Text] [Related]
2. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
3. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
[TBL] [Abstract] [Full Text] [Related]
4. Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
Mikhael S; Kurdi A; Khoueiry-Zgheib N; Tahtouh R; Nasr R; Hilal G
PLoS One; 2024; 19(3):e0298127. PubMed ID: 38489280
[TBL] [Abstract] [Full Text] [Related]
5. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
Gagliardi S; Mitruccio M; Di Corato R; Romano R; Aloisi A; Rinaldi R; Alifano P; Guerra F; Bucci C
Cell Commun Signal; 2024 Mar; 22(1):165. PubMed ID: 38448982
[TBL] [Abstract] [Full Text] [Related]
6. TOP2A modulates signaling via the AKT/mtor pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
7. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
8. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract] [Full Text] [Related]
9. Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Coleman N; Stephen B; Fu S; Karp D; Subbiah V; Ahnert JR; Piha-Paul SA; Wright J; Fessahaye SN; Ouyang F; Yilmaz B; Meric-Bernstam F; Naing A
Cancer Med; 2024 Feb; 13(3):e6877. PubMed ID: 38400671
[TBL] [Abstract] [Full Text] [Related]
10. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive Analysis of MICALL2 Reveals Its Potential Roles in EGFR Stabilization and ovarian cancer Cell Invasion.
Xia T; Ye F; Zhao W; Min P; Qi C; Wang Q; Zhao M; Zhang Y; Du J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203692
[TBL] [Abstract] [Full Text] [Related]
12. Bioactive Properties of
Rivas-García L; Crespo-Antolín L; Forbes-Hernández TY; Romero-Márquez JM; Navarro-Hortal MD; Arredondo M; Llopis J; Quiles JL; Sánchez-González C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203451
[No Abstract] [Full Text] [Related]
13. PAX2 is regulated by estrogen/progesterone through promoter methylation in endometrioid adenocarcinoma and has an important role in carcinogenesis via the AKT/mtor signaling pathway.
Chen H; Li L; Liu H; Qin P; Chen R; Liu S; Xiong H; Li Y; Yang Z; Xie M; Yang H; Jiang Q
J Pathol; 2024 Apr; 262(4):467-479. PubMed ID: 38185904
[TBL] [Abstract] [Full Text] [Related]
14. MK8722 initiates early-stage autophagy while inhibiting late-stage autophagy via FASN-dependent reprogramming of lipid metabolism.
Wang L; Zhu H; Shi Z; Chen B; Huang H; Lin G; Li J; Yu H; Xu S; Chen G; Ou R; Dai C
Theranostics; 2024; 14(1):75-95. PubMed ID: 38164137
[No Abstract] [Full Text] [Related]
15. Phase I Study of mtorC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mtor/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
16. Activation of PI3K/AKT/mtor signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract] [Full Text] [Related]
17. Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6.
Li S; Yi Z; Li M; Zhu Z
J Ovarian Res; 2023 Nov; 16(1):212. PubMed ID: 37940982
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
19. Identification of two immune subtypes and four hub immune-related genes in ovarian cancer through multiple analysis.
Tang Q; Zhang H; Tang R
Medicine (Baltimore); 2023 Oct; 102(40):e35246. PubMed ID: 37800814
[TBL] [Abstract] [Full Text] [Related]
20. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mtor axis.
Wang F; Zhang Y; Pang R; Shi S; Wang R
Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
[TBL] [Abstract] [Full Text] [Related]
[Next]
